keyword
Keywords Neoadjuvant chemotherapy of lu...

Neoadjuvant chemotherapy of lung cancer

https://read.qxmd.com/read/38462413/perioperative-immunotherapy-for-non-small-cell-lung-cancer-practical-application-of-emerging-data-and-new-challenges
#21
REVIEW
Angelica D'Aiello, Brendon Stiles, Nitin Ohri, Benjamin Levy, Perry Cohen, Balazs Halmos
Immune checkpoint inhibition, with or without chemotherapy, is an established standard of care for metastatic non-small cell lung cancer (NSCLC). For locally advanced NSCLC treated with chemoradiotherapy, consolidation immunotherapy has dramatically improved outcomes. Recently, immunotherapy has also been established as a valuable component of treatment for resectable NSCLC with pembrolizumab, atezolizumab, and nivolumab all approved for use in this setting. As more results read out from ongoing perioperative clinical trials, navigating treatment options will likely become increasingly complex for the practicing oncologist...
February 13, 2024: Clinical Lung Cancer
https://read.qxmd.com/read/38461929/evaluation-of-mpr-and-pcr-as-surrogate-endpoints-for-survival-in-randomized-controlled-trials-of-neoadjuvant-immune-checkpoint-blockade-in-resectable-in-non-small-cell-lung-cancer
#22
JOURNAL ARTICLE
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, Leeseul Kim, Luca Porcu, Antonio Nuccio, Giuseppe Viscardi, Roberto Ferrara, Giulia Veronesi, Patrick M Forde, Janis Taube, Everett Vokes, Christine M Bestvina, James M Dolezal, Matteo Sacco, Marta Monteforte, Tina Cascone, Marina C Garassino, Valter Torri
INTRODUCTION: Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate endpoints for event free survival (EFS) and overall survival (OS) in neoadjuvant trials for resectable non-small cell lung cancer (NSCLC). METHODS: A search of PubMed and archives of international conference abstracts was performed from June 2017 through October 31, 2023. Studies incorporating a neoadjuvant arm with immune checkpoint blockade alone or in combination with chemotherapy were included...
March 8, 2024: Journal of Thoracic Oncology
https://read.qxmd.com/read/38461767/population-based-survival-rates-after-curative-surgical-and-non-surgical-treatment-of-stage-iii-nsclc-since-2017
#23
JOURNAL ARTICLE
R A M Damhuis, C Dickhoff, I Bahce, S Senan
OBJECTIVES: In stage III non-small cell lung cancer (NSCLC), curative treatment approaches used to include neoadjuvant therapy followed by surgery, and definitive chemoradiotherapy followed by consolidation durvalumab (CRT-ICI). Surgical strategies included either neoadjuvant chemotherapy (CTx-surg) or chemoradiotherapy (CRT-surg). We studied the outcomes of these three radical intent strategies in the Netherlands Cancer Registry (NCR) for patients diagnosed from 2017 to 2021. MATERIALS AND METHODS: Patients with clinical stage III NSCLC (TNM edition 8) were identified in the NCR after excluding patients with known driver mutations, ECOG performance status >=2, N3-disease and those undergoing sequential chemoradiotherapy or single modality/palliative treatments...
March 7, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38454928/perioperative-immunotherapy-for-stage-ii-iii-non-small-cell-lung-cancer-a-meta-analysis-base-on-randomized-controlled-trials
#24
Anping Yu, Feng Fu, Xiongying Li, Mengxin Wu, Meijian Yu, Wenxiong Zhang
BACKGROUND: In recent years, we have observed the pivotal role of immunotherapy in improving survival for patients with non-small cell lung cancer (NSCLC). However, the effectiveness of immunotherapy in the perioperative (neoadjuvant + adjuvant) treatment of resectable NSCLC remains uncertain. We conducted a comprehensive analysis of its antitumor efficacy and adverse effects (AEs) by pooling data from the KEYNOTE-671, NADIM II, and AEGEAN clinical trials. METHODS: For eligible studies, we searched seven databases...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38453764/combined-resection-of-lung-cancer-and-thoracic-aortic-wall-with-simultaneous-thoracic-aortic-endografting-a-case-report
#25
JOURNAL ARTICLE
Hiroaki Komatsu, Nao Furukawa, Hirotaka Kinoshita, Atsutaka Aratame, Toshio Baba, Kazunori Okabe
BACKGROUND: Combined resection of lung cancer and the thoracic aortic wall with thoracic aortic endografting has been reported. However, whether the resection and endografting should be performed simultaneously or in two steps remains controversial. CASE PRESENTATION: A 68-year-old man was referred to our hospital because of left chest pain. Chest contrast-enhanced computed tomography revealed a huge tumor of the left lower lung lobe, and invasion to the aortic wall was suspected...
March 8, 2024: Surgical Case Reports
https://read.qxmd.com/read/38451524/neoadjuvant-adjuvant-vs-neoadjuvant-only-pd-1-and-pd-l1-inhibitors-for-patients-with-resectable-nsclc-an-indirect-meta-analysis
#26
JOURNAL ARTICLE
Yixin Zhou, Anlin Li, Hui Yu, Yuhong Wang, Xuanye Zhang, Huijuan Qiu, Wei Du, Linfeng Luo, Sha Fu, Li Zhang, Shaodong Hong
IMPORTANCE: Neoadjuvant therapy combining programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has demonstrated significant improvement in pathologic response and survival rates among patients with resectable non-small cell lung cancer (NSCLC). However, it remains controversial whether PD-1 blockade therapy given before and after surgery (neoadjuvant-adjuvant treatment) is associated with better outcomes than when given only before surgery (neoadjuvant-only treatment)...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38440697/metastatic-small-cell-bladder-cancer-treated-with-sequential-systemic-therapy-including-pembrolizumab-and-amrubicin-a%C3%A2-case%C3%A2-report
#27
Kazutaka Mitani, Ichiro Tsuboi, Gen Tanaka, Saori Yosioka, Shuhei Yokoyama, Yusuke Kobayashi, Hirochika Nakajima, Taichi Nagami, Kohei Ogawa, Koichiro Wada
INTRODUCTION: Small cell bladder cancer is a relatively rare tumor, representing <1% of all bladder tumors. Amrubicin monotherapy is used as second-line treatment for small cell lung cancer in Japan. CASE PRESENTATION: A 79-year-old woman presented with gross hematuria and was diagnosed with small cell bladder cancer (T2 or higher). Neoadjuvant chemotherapy with etoposide and cisplatin resulted in a partial response. Robot-assisted radical cystectomy was performed, and radical resection was achieved...
March 2024: IJU case reports
https://read.qxmd.com/read/38439872/complete-response-in-patient-with-locally-advanced-lung-large-cell-neuroendocrine-carcinoma-under-sintilimab-plus-platinum-based-chemotherapy-a-case-report
#28
Jinpeng Huang, Feiye Wang, Xiaohua Du, Yongfeng Li, Yuanyuan Zhuang, Ziyan Gan, Shunqin Long, Wanyin Wu, Xiaobing Yang
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is an uncommon subtype of lung cancer with bleak prognosis. Its optimal treatment remains undetermined due to its malignancy. A 66-year-old man diagnosed with unresectable locally advanced LCNEC exhibited partial radiographic response to chemo-immunotherapy. He underwent salvage surgery after 4 rounds of docetaxel/nedaplatin (DP) regimen plus sintilimab, a highly selective monoclonal antibody which targets human anti-programmed death-ligand 1 (PD-L1). In addition, the pathologic examination of the excision demonstrated that there were no viable residuary tumor cells...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38438179/extra-abdominal-cytoreductive-techniques-in-ovarian-cancer-how-far-can-should-we-go
#29
REVIEW
Ryan M Kahn, Suk-Joon Chang, Dennis S Chi
Complex surgery is an essential component in the management of advanced ovarian cancer. Furthermore, achieving complete gross resection in cytoreductive surgery appears to be associated with significant survival benefits in patients with advanced ovarian cancer. The goal of this review is to demonstrate the advancement of surgical techniques in gynecologic oncology surgery, including resection of disease within the intrathoracic and inguinal regions. This progress has expanded the option of surgery to more patients, especially those who would have previously been deemed inoperable...
March 4, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38425343/platinum-based-neoadjuvant-chemotherapy-upregulates-sting-ifn-pathway-expression-and-promotes-tils-infiltration-in-nsclc
#30
JOURNAL ARTICLE
Huan Gao, Xiaoni Zhang, Mengdi Ren, Aimin Jiang, Na Liu, Jingjing Wang, Xiaoqiang Zheng, Xuan Liang, Zhiping Ruan, Tao Tian, Xiao Fu, Yu Yao
OBJECTIVES: To evaluate the effects of platinum-based neoadjuvant chemotherapy (NACT) on the STING/IFN pathway and tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC), as well as clinicopathological factors affecting patient survival. MATERIALS AND METHODS: A total of 68 patients aged 34-77 years with NSCLC who received neoadjuvant chemotherapy and surgical treatment from March 2012 to February 2019 were reviewed, and the clinical pathological data and paired tissue specimens before and after NACT were collected...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38423786/deep-semisupervised-transfer-learning-for-fully-automated-whole-body-tumor-quantification-and-prognosis-of-cancer-on-pet-ct
#31
JOURNAL ARTICLE
Kevin H Leung, Steven P Rowe, Moe S Sadaghiani, Jeffrey P Leal, Esther Mena, Peter L Choyke, Yong Du, Martin G Pomper
Automatic detection and characterization of cancer are important clinical needs to optimize early treatment. We developed a deep, semisupervised transfer learning approach for fully automated, whole-body tumor segmentation and prognosis on PET/CT. Methods: This retrospective study consisted of 611 18 F-FDG PET/CT scans of patients with lung cancer, melanoma, lymphoma, head and neck cancer, and breast cancer and 408 prostate-specific membrane antigen (PSMA) PET/CT scans of patients with prostate cancer. The approach had a nnU-net backbone and learned the segmentation task on 18 F-FDG and PSMA PET/CT images using limited annotations and radiomics analysis...
February 29, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38414317/subsequent-surgical-treatment-or-maintenance-immunotherapy-in-stage-iii-lung-cancer-patients-achieving-a-favorable-response-following-neoadjuvant-immunotherapy-a-matched-retrospective-cohort-study-from-the-surgical-perspective
#32
JOURNAL ARTICLE
Fuqiang Dai, Cong Chen, Guanyu Zhou, Xintian Wang, Longyong Mei, Nanzhi Luo, Wenjing Zhou, Tao Li, Bo Deng, Lunxu Liu, Yun Wang
BACKGROUND: Current treatment strategies for advanced non-small cell lung cancer (NSCLC) are highly individualized and subject to ongoing debates. In the era of immunotherapy, surgery assumes a critical role. The aim of this study was to investigate if subsequent surgical intervention, following a favorable response to immunotherapy and chemotherapy, could yield a more favorable prognosis for patients with advanced stage III NSCLC compared to the continuation of immunotherapy and chemotherapy...
February 27, 2024: Thoracic Cancer
https://read.qxmd.com/read/38410557/efficacy-and-safety-of-neoadjuvant-tislelizumab-combined-with-chemotherapy-in-locally-advanced-non-small-cell-lung-cancer-a-retrospective-cohort-study
#33
JOURNAL ARTICLE
Hao Chen, Jiarong Zhang, Chun Chen, Wei Zheng, Bin Zheng
BACKGROUND: At present, comprehensive treatment is still the main approach for locally advanced non-small cell lung cancer (NSCLC) patients, and the research of neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced NSCLC is still in progress. We conducted this research in order to investigate the efficacy and safety of neoadjuvant tislelizumab combined with chemotherapy in the treatment of locally advanced NSCLC. METHODS: From January 1, 2021, to November 30, 2022, 12 patients with locally advanced NSCLC at the Fujian Medical University Union Hospital were retrospectively analyzed...
January 30, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38410203/the-efficacy-of-neoadjuvant-immunotherapy-combined-with-chemotherapy-in-resectable-stage-ii-iv-non-small-cell-lung-cancer-a-preliminary-study
#34
JOURNAL ARTICLE
Chengbin Tang, Bo Yang, Yang Liu
BACKGROUND: Lung cancer is currently the world's leading malignancy in terms of morbidity and mortality. Neoadjuvant therapy is widely used in clinic to improve R0 resection rates and long-term survival after surgery, and patients with locally resectable non-small cell lung cancer (NSCLC) may benefit from neoadjuvant therapy. METHODS: Data from 78 patients with stage II to IV NSCLC who had received neoadjuvant immunotherapy combined with chemotherapy from January 2019 to May 2022 were collected...
January 31, 2024: Translational Cancer Research
https://read.qxmd.com/read/38385995/neoadjuvant-savolitinib-targeted-therapy-for-stage-iiib-n3-lung-adenocarcinoma-harboring-mesenchymal-epithelial-transition-exon-14-skipping-mutation-a-case-report-and-literature-review
#35
JOURNAL ARTICLE
Lei Chen, Jin-Feng Chen, Jin-Tao He, Hao Rong, Xiang Zhuang, Jun Peng
Savolitinib is a selective inhibitor that specifically targets the phosphorylation of mesenchymal-epithelial transition (MET) kinase. It has demonstrated significant inhibitory effects on the proliferation of tumor cells with METex14 skipping mutation, making it a promising treatment option. While it is the first approved small-molecule inhibitor specifically targeting MET kinase in China, there is limited information about its efficacy as neoadjuvant therapy for patients with supraclavicular lymph node metastasis (N3)...
February 23, 2024: Anti-cancer Drugs
https://read.qxmd.com/read/38372058/the-emerging-perioperative-treatment-paradigm-for-non-small-cell-lung-cancer-a-narrative-review
#36
JOURNAL ARTICLE
Petros Christopoulos
BACKGROUND AND OBJECTIVE: The management of resectable non-small cell lung cancer (NSCLC) has relied on surgery and adjuvant chemotherapy for the past two decades, but is now radically changing through the introduction of immunotherapy and targeted drugs. This review was conducted to summarize recent developments and highlight future directions. METHODS: A literature search for randomized phase 2/3 trials on the treatment of early-stage NSCLC was performed based on PubMed and the content on major oncology congresses during the last 3 years...
February 5, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38354688/tumor-microenvironment-tme-and-single-source-dual-energy-ct-ssdect-on-assessment-of-inconformity-between-recist1-1-and-pathological-remission-in-neoadjuvant-immunotherapy-of-nsclc
#37
JOURNAL ARTICLE
Chao Sun, Xiaobo Ma, Fanyang Meng, Xi Chen, Xu Wang, Wenyu Sun, Yinghui Xu, Hua He, Huimao Zhang, Kewei Ma
BACKGROUND: The inconformity (IC) between pathological and imaging remissions after neoadjuvant immunotherapy in patients with NSCLC can affect the evaluation of curative effect of neoadjuvant therapy and the decision regarding the chance of surgery. MATERIALS AND METHODS: Patients who achieved disease control(CR/PR/SD) after neoadjuvant chemoimmunotherapy from a clinical trial (NCT04326153) and after neoadjuvant chemotherapy during the same period were enrolled in this study...
February 13, 2024: Neoplasia: An International Journal for Oncology Research
https://read.qxmd.com/read/38353107/neoscore-ii-three-vs-four-cycles-of-neoadjuvant-sintilimab%C3%A2-%C3%A2-chemotherapy-for-squamous-non-small-cell-lung-cancer
#38
REVIEW
Xinyi Zhang, Miner Shao, Jie Yao, Lufeng Zhao, Lili Li, Mengyao Chen, Yixin Zhang, Huiying Liu, Zexin Chen, Baizhou Li, Zuqun Wu, Junqiang Fan, Fuming Qiu
Immune checkpoint inhibitors (ICIs) plus chemotherapy has demonstrated efficacy in resectable non-small-cell lung cancer (NSCLC), yet the optimal period of neoadjuvant immunochemotherapy is undetermined. In a phase II study (neoSCORE, NCT04459611), more neoadjuvant therapy cycles appeared to provide greater pathological remission, and patients with squamous NSCLC had a better major pathological response rate than those with nonsquamous NSCLC. Sintilimab, a monoclonal anti-PD-1 antibody, has shown encouraging antitumor activity and safety in multiple cancers, including NSCLC...
February 14, 2024: Future Oncology
https://read.qxmd.com/read/38345887/outcomes-of-surgically-treated-n2-positive-non-small-cell-lung-cancer
#39
JOURNAL ARTICLE
Joana Rei, Patrícia Castro, Miguel Guerra, José Miranda
INTRODUCTION: The role of surgery in the treatment of stage IIB/IIIA lung cancer is still a matter of debate. To assess the outcomes of N2-positive patients, we performed a retrospective 10-year study including all patients with histologically proven N2 disease submitted to lung resection surgery by the same surgical team in three different hospitals. MATERIALS AND METHODS: Demographic, clinical, surgical and survival data were collected from patients' clinical registries...
February 9, 2024: Port J Card Thorac Vasc Surg
https://read.qxmd.com/read/38329515/-advances-in-the-targeted-treatment-of-non-small-cell-lung-cancer
#40
REVIEW
Lea Ruge, Felix John, Heather Scharpenseel, Jürgen Wolf
Non-small cell lung cancer (NSCLC) paradigmatically shows the potential of personalized and therefore precise cancer treatment. For around one third of the patients, predominantly suffering from adenocarcinoma, targetable driver mutations could be characterized in the meantime. Targeted therapies, mostly with kinase inhibitors, achieve impressive advances in the prolongation of overall survival often over many years and excellent quality of life in patients with advanced NSCLC. Targeted treatment is also increasingly evaluated as adjuvant or neoadjuvant treatment in early inoperable stages of NSCLC...
February 8, 2024: Inn Med (Heidelb)
keyword
keyword
52838
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.